TP-102

TP-102

Clinical Case Compassionate Use

TP-102 is the first top­i­cal bac­te­rio­phage cock­tail devel­oped specif­i­cal­ly to treat dia­bet­ic foot ulcers.

TP-102 has shown a favor­able safe­ty pro­file and pre­lim­i­nary effi­ca­cy in clin­i­cal tri­als pro­mot­ing accel­er­at­ed heal­ing and bac­te­r­i­al clear­ance with no sys­temic adverse effects report­ed.

The Potential to Transform the Care of Diabetic Foot Infections

TP-102

The Potential to Transform the Care of Diabetic Foot Infections

Pre­ci­sion against pathogens. Heal­ing beyond antibi­otics.

This report describes the use of phage ther­a­py (TP-102) for dia­bet­ic foot ulcers under a com­pas­sion­ate use pro­gram and sum­ma­rizes avail­able data on effi­ca­cy and tol­er­a­bil­i­ty.

Clinical case

  • 59 years man
  • Dia­betes mel­li­tus type 2
  • Insulin treat­ment
  • Hyper­ten­sion, dys­lipi­demia
  • IHD-past coro­nary cath: 2 stents
  • Past smok­er
  • Obe­si­ty (Weight 103kg)
  • Fail­ure of skin graft, per­sis­tent MRSA infec­tion.
  • Prox­i­mal prop­a­ga­tion of the infec­tion.
  • Leg CT no evi­dence of bone involve­ment.
  • V.A.C and antimi­cro­bial treat­ment.

Local phage cock­tail treat­ment pro­to­col: 

One mL of solu­tion was applied top­i­cal­ly per cm3 of tar­get ulcer.
Every oth­er day, 7 treat­ments.

Phage therapy

START

Phage ther­a­py

image15

2 MONTHS

Post phage ther­a­py

post phage therapy

6 MONTHS

Post phage ther­a­py

RECOVERED

Source

Dekel, M., Albagli, A., Kedar, D., Nir-Paz, R., Haz­an, R., Onal­lah, H., Ben-Ami, R., Jones-Dias, D., Bar­reto, M., & Corte-Real, S. (2023). Suc­cess­ful treat­ment of com­pli­cat­ed dia­bet­ic foot infec­tions using a nov­el top­i­cal bac­te­rio­phage cock­tail TP-102. Tel Aviv Sourasky Med­ical Cen­ter; Technophage S.A.

Pub­lish on Technophage, S.A. linkedin page: https://www.linkedin.com/company/technophage-sa/posts/

Con­tact Us